EATL
MCID: ENT008
MIFTS: 36

Enteropathy-Associated T-Cell Lymphoma (EATL)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Enteropathy-Associated T-Cell Lymphoma

MalaCards integrated aliases for Enteropathy-Associated T-Cell Lymphoma:

Name: Enteropathy-Associated T-Cell Lymphoma 52 58 71
High-Grade Pleomorphic Peripheral T-Cell Lymphoma 52
Enteropathy-Type T-Cell Lymphoma 58
Intestinal T-Cell Lymphoma 58
Eatcl 52
Eatl 58
Ettl 58

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases
Rare haematological diseases


External Ids:

ICD10 32 C86.2
MESH via Orphanet 44 D058527
ICD10 via Orphanet 33 C86.2
UMLS via Orphanet 72 C0456889
Orphanet 58 ORPHA86880
UMLS 71 C0456889

Summaries for Enteropathy-Associated T-Cell Lymphoma

MalaCards based summary : Enteropathy-Associated T-Cell Lymphoma, also known as high-grade pleomorphic peripheral t-cell lymphoma, is related to lymphoma and celiac disease 1. An important gene associated with Enteropathy-Associated T-Cell Lymphoma is SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase), and among its related pathways/superpathways are Akt Signaling and Reelin Pathway (Cajal-Retzius cells). The drugs Methotrexate and Pirarubicin have been mentioned in the context of this disorder. Affiliated tissues include t cells, nk cells and small intestine, and related phenotypes are hematopoietic system and immune system

Related Diseases for Enteropathy-Associated T-Cell Lymphoma

Diseases related to Enteropathy-Associated T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 lymphoma 11.0
2 celiac disease 1 11.0
3 refractory celiac disease 10.7
4 peripheral t-cell lymphoma 10.7
5 lymphoma, hodgkin, classic 10.6
6 lymphoma, non-hodgkin, familial 10.6
7 intestinal perforation 10.6
8 diarrhea 10.5
9 intestinal obstruction 10.4
10 t-cell lymphoma, subcutaneous panniculitis-like 10.4
11 b-cell lymphoma 10.3
12 gastrointestinal lymphoma 10.3
13 autoimmune disease 10.2
14 adult t-cell leukemia 10.2
15 inflammatory bowel disease 10.2
16 anaplastic large cell lymphoma 10.2
17 toxic shock syndrome 10.2
18 acute kidney failure 10.2
19 fibrosarcoma of bone 10.2
20 histiocytosis 10.2
21 infertility 10.2
22 t-cell lymphoblastic leukemia/lymphoma 10.2
23 peptic ulcer disease 10.2
24 reticulosarcoma 10.2
25 ulcerative colitis 10.2
26 crohn's disease 10.2
27 hypereosinophilic syndrome 10.2
28 autoimmune enteropathy 10.2
29 leukemia, t-cell, chronic 10.2
30 t-cell non-hodgkin lymphoma 10.2
31 severe immune-mediated enteropathy 10.2
32 peritonitis 10.2
33 marginal zone b-cell lymphoma 10.1
34 nodal marginal zone lymphoma 10.1
35 protein-losing enteropathy 10.1
36 hypothyroidism 10.1
37 splenomegaly 10.1
38 b-cell non-hodgkin lymphoma 10.1
39 lymphoproliferative syndrome 10.1
40 t-cell adult acute lymphocytic leukemia 10.1
41 hepatosplenic t-cell lymphoma 10.1
42 atrial standstill 1 10.1
43 burkitt lymphoma 10.1
44 intussusception 10.1
45 osteoporosis 10.1
46 anemia, autoimmune hemolytic 10.1
47 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
48 hypereosinophilic syndrome, idiopathic 10.1
49 neutrophilic dermatosis, acute febrile 10.1
50 myocardial infarction 10.1

Graphical network of the top 20 diseases related to Enteropathy-Associated T-Cell Lymphoma:



Diseases related to Enteropathy-Associated T-Cell Lymphoma

Symptoms & Phenotypes for Enteropathy-Associated T-Cell Lymphoma

MGI Mouse Phenotypes related to Enteropathy-Associated T-Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.26 CCL11 CD3G ITGAE SETD2
2 immune system MP:0005387 8.92 CCL11 CD3G ITGAE SETD2

Drugs & Therapeutics for Enteropathy-Associated T-Cell Lymphoma

Drugs for Enteropathy-Associated T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
2
Pirarubicin Investigational Phase 4 72496-41-4
3
Epirubicin Approved Phase 2 56420-45-2 41867
4
Melphalan Approved Phase 2 148-82-3 460612 4053
5
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
6
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
7
Carmustine Approved, Investigational Phase 2 154-93-8 2578
8
leucovorin Approved Phase 1, Phase 2 58-05-9 6006 143
9
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
10
Daunorubicin Approved Phase 2 20830-81-3 30323
11
Vincristine Approved, Investigational Phase 1, Phase 2 57-22-7, 2068-78-2 5978
12
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
13
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
14
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
15
Ifosfamide Approved Phase 2 3778-73-2 3690
16
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
17
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
18
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
19
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
20 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
21
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
22
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
23
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
24
Gemcitabine Approved Phase 2 95058-81-4 60750
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
26
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
27
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
28
nivolumab Approved Phase 2 946414-94-4
29
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
31
tipifarnib Investigational Phase 2 192185-72-1 159324
32
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
33
Cortisone Experimental Phase 1, Phase 2 53-06-5 222786
34 Immunosuppressive Agents Phase 1, Phase 2
35 Immunologic Factors Phase 1, Phase 2
36 Tin Fluorides Phase 2
37 Proteasome Inhibitors Phase 2
38 Folic Acid Antagonists Phase 1, Phase 2
39 Vitamin B Complex Phase 1, Phase 2
40 Folate Phase 1, Phase 2
41 Vitamin B9 Phase 1, Phase 2
42 Immunoglobulins Phase 2
43 Antibodies Phase 2
44 Antibodies, Monoclonal Phase 2
45 10-deazaaminopterin Phase 1, Phase 2
46 Immunoglobulins, Intravenous Phase 2
47 Immunoconjugates Phase 2
48 Etoposide phosphate Phase 1, Phase 2
49 Hormones Phase 1, Phase 2
50 Antineoplastic Agents, Hormonal Phase 1, Phase 2

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
3 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT04021082 Phase 2, Phase 3 Cerdulatinib
4 A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
5 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
6 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
7 An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy Completed NCT00901147 Phase 2 panobinostat and bortezomib
8 A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma Completed NCT00322985 Phase 2 Lenalidomide
9 A Phase I/II of Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma Completed NCT00787527 Phase 1, Phase 2 Zolinza (vorinostat);Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
10 Phase 2 Study of Brentuximab Vedotin Associated With CHP Followed by Consolidation With High-dose Therapy / Autologous Stem-cell Transplantation as Frontline Treatment of Patients With Enteropathy-associated T-cell Lymphoma Type 1. Recruiting NCT03217643 Phase 2 Brentuximab Vedotin
11 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Recruiting NCT02588651 Phase 2 Brentuximab vedotin
12 A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas Recruiting NCT03598998 Phase 1, Phase 2 Pralatrexate
13 A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Prednisone
14 An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Recruiting NCT02464228 Phase 2 Tipifarnib
15 A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
16 CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study Active, not recruiting NCT01719835 Phase 2 Cyclophosphamide;Gemcitabine;Doxorubicin;Vincristine;Prednisolone;methylprednisolone;Cisplatin
17 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL) Active, not recruiting NCT02533700 Phase 2 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
18 Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) Terminated NCT03075553 Phase 2
19 A Phase II Study To Determine The Safety and Efficacy Of The Combination of Vorinostat and Bortezomib In Patients With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma Terminated NCT00810576 Phase 2 Vorinostat;Bortezomib
20 Phase I Study of the Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward IL-2/IL-15R Beta (CD122) That Blocks IL-15 Action In Patients With Refractory Celiac Disease Completed NCT01893775 Phase 1
21 Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT01590732 Phase 1 Carboplatin;Etoposide;Ifosfamide;Romidepsin
22 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies Completed NCT00697346 Phase 1 Alisertib
23 A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies. Recruiting NCT03905135 Phase 1 rhIL-15
24 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting NCT03049449 Phase 1 Cyclophosphamide;Fludarabine
25 A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma Terminated NCT00671112 Phase 1 Bortezomib;Everolimus
26 Prospective Randomized Comparison Between Axial- and Lateral-viewing Capsule Endoscopy Systems in Celiac Patients: a Pilot Study Unknown status NCT03095573
27 A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma Completed NCT02652715
28 MRI Assessment in Newly Diagnosed Coeliac Disease and Following Gluten-free Diet Treatment Completed NCT02551289
29 Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer Recruiting NCT01787409
30 Assessing the Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh Through Pilot Intervention Recruiting NCT03189004
31 AMG 714 Expanded Access Program Available NCT03439475

Search NIH Clinical Center for Enteropathy-Associated T-Cell Lymphoma

Genetic Tests for Enteropathy-Associated T-Cell Lymphoma

Anatomical Context for Enteropathy-Associated T-Cell Lymphoma

MalaCards organs/tissues related to Enteropathy-Associated T-Cell Lymphoma:

40
T Cells, Nk Cells, Small Intestine, Colon, B Cells, Lymph Node, Bone Marrow

Publications for Enteropathy-Associated T-Cell Lymphoma

Articles related to Enteropathy-Associated T-Cell Lymphoma:

(show top 50) (show all 491)
# Title Authors PMID Year
1
Epidemiological, pathological and immunohistochemical aspects of 125 cases of feline lymphoma in Southern Brazil. 61
31461200 2020
2
Monomorphic Epitheliotropic Intestinal T Cell Lymphoma of the Appendix: a Case Report and Review of Literature. 61
31970655 2020
3
Monomorphic epitheliotropic intestinal T-cell lymphoma of the duodenum: an aggressive disease. 61
32536535 2020
4
Type II enteropathy-associated T cell lymphoma in the duodenum: A rare case report. 61
32501967 2020
5
Equine Intestinal Lymphoma: Clinical-Pathological Features, Immunophenotype, and Survival. 61
32202217 2020
6
Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas. 61
31773249 2020
7
Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis. 61
32420596 2020
8
Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports. 61
32337203 2020
9
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. 61
31709579 2020
10
Refractory celiac disease type II: An atypical case highlighting limitations of the current classification system. 61
32010998 2020
11
The intracellular intensity of CD3 on aberrant intraepithelial lymphocytes is a prognostic factor of the progression to overt lymphoma in Refractory Celiac Disease Type II (RCD-II/Pre-Enteropathy-Associated T cell Lymphoma). 61
32015237 2020
12
T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: review and update. 61
31727264 2020
13
[Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological analysis of twelve cases]. 61
31914529 2020
14
Tumour-specific microRNA expression pattern in canine intestinal T-cell-lymphomas. 61
31997569 2020
15
Gastrointestinal T- and NK-cell lymphomas and indolent lymphoproliferative disorders. 61
31522873 2020
16
Enteropathy-associated T-cell Lymphoma (EATL) with intracranial metastasis : a rare and dismal condition. 61
32233276 2020
17
Monomorphic Epitheliotropic Intestinal T cell Lymphoma: a Rare Cause of Chronic Diarrhea. 61
30761475 2019
18
Characterization of the fecal microbiome in cats with inflammatory bowel disease or alimentary small cell lymphoma. 61
31844119 2019
19
Anaplastic Large T-Cell Lymphoma in the Intestine of Dogs. 61
31170900 2019
20
Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. 61
31493002 2019
21
Bone marrow involvement by monomorphic epitheliotropic intestinal T-cell lymphoma. 61
31240703 2019
22
[Current standard in diagnostic and therapy of peripheral T-cell lymphoma]. 61
31594013 2019
23
A case of celiac disease with type I enteropathy-associated T-cell lymphoma in a Japanese male patient. 61
31603739 2019
24
An Unusual Case of Enteropathy-associated T-cell Lymphoma Type 2 with Pulmonary Metastasis. 61
31720182 2019
25
Two cases of monomorphic epitheliotropic intestinal T-cell lymphoma associated with coeliac disease. 61
31361171 2019
26
[Mesenteric lymph node cavitation in celiac disease: Report of four cases and literature review]. 61
31155369 2019
27
DIFFERENTIATING ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA TYPE 2 FROM INFLAMMATORY BOWEL DISEASE IN A SNOW LEOPARD (UNCIA UNCIA). 61
31260218 2019
28
Successful treatment of monomorphic epitheliotropic intestinal T cell lymphoma with pralatrexate. 61
30173289 2019
29
Monomorphic epitheliotropic intestinal T cell lymphoma presenting in weblike feature. 61
30576648 2019
30
Diffuse large B-cell lymphoma of the small intestine in a patient with refractory coeliac disease. 61
31025641 2019
31
Management of celiac disease in daily clinical practice. 61
30528262 2019
32
Gastrointestinal: Endoscopic findings of monomorphic epitheliotropic intestinal T-cell lymphoma. 61
30225983 2019
33
Monomorphic epitheliotropic intestinal T-cell lymphoma with T-cell receptor (TCR) of silent phenotype shows rearrangement of TCRβ or TCRγ gene. 61
30576040 2019
34
Immunohistochemical Profiling of Canine Intestinal T-Cell Lymphomas. 61
30278836 2019
35
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia. 61
31354304 2019
36
[Acute intestinal intussusception revealing intestinal T-cell lymphoma in adults]. 61
31558950 2019
37
A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues. 61
30268943 2019
38
Truth lies below: A case report and literature review of typical appearing polyps yet with an atypical diagnosis. 61
30705732 2019
39
[Enteropathy-associated T-cell lymphoma coexisting with composite lymphoma composed of DLBCL and PTCL]. 61
31068515 2019
40
Clinical and immunophenotypic findings in 4 forms of equine lymphoma. 61
30651648 2019
41
Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders. 61
30757928 2019
42
Rare T-Cell Subtypes. 61
30596220 2019
43
Hypocalcemia Revealing an Enteropathy-Associated T-cell Lymphoma. 61
30858951 2019
44
Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. 61
30151671 2018
45
Primary cutaneous peripheral T-cell lymphoma with a late relapse solely in the ileum mimicking monomorphic epitheliotropic intestinal T-cell lymphoma. 61
30477646 2018
46
Intestinal T-cell and NK/T-cell lymphomas: A clinicopathological study of 27 Chinese patients. 61
30317149 2018
47
Risks for lymphoma and gastrointestinal carcinoma in patients with newly diagnosed adult-onset celiac disease: Consequences for follow-up: Celiac disease, lymphoma and GI carcinoma. 61
30574319 2018
48
Pathological features of intestinal T-cell lymphoma in Shiba dogs in Japan. 61
29575510 2018
49
Recurrent monomorphic epitheliotropic intestinal T-cell lymphoma with aberrant CD20 expression: An implication for anti-CD20 (rituximab) antibody therapy? 61
30402988 2018
50
Update on Gastrointestinal Lymphomas. 61
30407861 2018

Variations for Enteropathy-Associated T-Cell Lymphoma

Expression for Enteropathy-Associated T-Cell Lymphoma

Search GEO for disease gene expression data for Enteropathy-Associated T-Cell Lymphoma.

Pathways for Enteropathy-Associated T-Cell Lymphoma

Pathways related to Enteropathy-Associated T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.28 ITGAE CD3G CCL11
2 10.63 ITGAE CD3G

GO Terms for Enteropathy-Associated T-Cell Lymphoma

Cellular components related to Enteropathy-Associated T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.62 ITGAE CD3G

Sources for Enteropathy-Associated T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....